Schiff J M, Fisher M M, Jones A L, Underdown B J
J Cell Biol. 1986 Mar;102(3):920-31. doi: 10.1083/jcb.102.3.920.
Asialoglycoproteins are taken up by the rat liver for degradation; rat polymeric IgA is taken up via a separate receptor, secretory component (SC), for quantitative delivery to bile. There is negligible uptake of these ligands by the converse receptor, and only a low level of missorting of ligands to opposite destinations. The two pathways are not cross-inhibitable and operate independently (Schiff, J.M., M. M. Fisher, and B. J. Underdown, 1984, J. Cell Biol., 98:79-89). We report here that when human IgA is presented as a ligand in the rat, it is processed using elements of both pathways. To study this in detail, different IgA fractions were prepared using two radiolabeling methods that provide separate probes for degradation or re-secretion. Behavior of intravenously injected human polymeric IgA in the rat depended on its binding properties. If deprived of SC binding activity by affinity adsorption or by reduction and alkylation, greater than 80% of human IgA was degraded in hepatic lysosomes; radioactive catabolites were released into bile by a leupeptin-inhibitable process. If prevented from binding to the asialoglycoprotein receptor by competition or by treatment with galactose oxidase, human IgA was cleared and transported to bile directly via SC, but its uptake was about fivefold slower than rat IgA. Untreated human IgA was taken up rapidly by the asialoglycoprotein receptor, but depended on SC binding to get to bile: the proportion secreted correlated 1:1 with SC binding activity determined in vitro, and the IgA was released into bile with SC still attached. These results demonstrate that human IgA is normally heterovalent: it is first captured from blood by the asialoglycoprotein receptor, but escapes the usual fate of asialoglycoproteins by switching to SC during transport. Since the biliary transit times of native human and rat IgA are the same, it is probable that the receptor switching event occurs en route. This implies that the two receptors briefly share a common intracellular compartment.
去唾液酸糖蛋白被大鼠肝脏摄取用于降解;大鼠聚合IgA通过一个独立的受体——分泌成分(SC)被摄取,以便定量输送到胆汁中。这些配体被反向受体摄取的量可忽略不计,且仅有少量配体被错误分选到相反的目的地。这两条途径不会相互抑制,而是独立运作(希夫,J.M.,M.M.费舍尔,和B.J.安德当,1984年,《细胞生物学杂志》,98:79 - 89)。我们在此报告,当人IgA作为配体在大鼠体内呈现时,它会利用这两条途径的元件进行处理。为了详细研究这一点,使用两种放射性标记方法制备了不同的IgA组分,这两种方法为降解或再分泌提供了单独的探针。静脉注射的人聚合IgA在大鼠体内的行为取决于其结合特性。如果通过亲和吸附或还原烷基化使其失去与SC的结合活性,超过80%的人IgA会在肝溶酶体中降解;放射性分解代谢产物通过一种亮抑酶肽可抑制的过程释放到胆汁中。如果通过竞争或用半乳糖氧化酶处理阻止其与去唾液酸糖蛋白受体结合,人IgA会被清除并直接通过SC转运到胆汁中,但其摄取速度比大鼠IgA慢约五倍。未处理的人IgA被去唾液酸糖蛋白受体快速摄取,但依赖于与SC的结合才能到达胆汁:分泌的比例与体外测定的SC结合活性呈1:1相关,并且IgA在SC仍附着的情况下释放到胆汁中。这些结果表明人IgA通常是异价的:它首先被去唾液酸糖蛋白受体从血液中捕获,但在运输过程中通过转换到SC而逃脱了去唾液酸糖蛋白的通常命运。由于天然人IgA和大鼠IgA在胆汁中的转运时间相同,受体转换事件很可能发生在途中。这意味着这两种受体短暂共享一个共同的细胞内区室。